Overview

Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1

Status:
Unknown status

Trial end date:
2009-03-01

Target enrollment:

Participant gender:

Summary

To investigate the effects of rhIGF-I/rhIGFBP-3 treatment for 24 weeks on endurance, ambulation, cognitive functioning, insulin resistance, lipid levels, muscle function and strength, pain, gastrointestinal functioning, and quality of life endpoints in DM1 patients

Phase:

Phase 2

Details

Lead Sponsor:

Insmed Incorporated

Collaborator:

Muscular Dystrophy Association

Treatments:

Insulin
Insulin, Globin Zinc
Mitogens